Literature DB >> 32273131

Expression analysis of immune-regulatory molecules HLA-G, HLA-E and IDO in endometrial cancer.

Hamza Ben Yahia1, Nadia Boujelbene2, Wafa Babay1, Inès Ben Safta3, Sabrine Dhouioui1, Inès Zemni3, Mohamed Ali Ayadi3, Lamia Charfi4, Hadda Imene Ouzari1, Vera Rebmann5, Roberta Rizzo6, Karima Mrad2, Maha Driss4, Inès Zidi7.   

Abstract

HLA-G has been widely implicated in advanced cancers through different pathways of immunosuppression allowing tumor escape. Contrarily, HLA-E has a controversial role in the tumor escape from the immune system. IDO catabolic enzyme is known to be up-regulated in many tumors types allowing their immune escape. Based on these considerations, we investigated the expression of HLA-G, HLA-E and IDO molecules in endometrial cancer (EC) and their association with prognostic clinicopathologic parameters. Their expression were checked in tumoral and adjacent endometrial tissues. Both HLA-G and IDO immunostaining were significantly increased in EC tissues compared to normal residual endometrial glands (Mann Whitney U-test, p = 0.0001 and p = 0,020 respectively). However, HLA-E was highly expressed in tumoral tissues as well as in normal residual endometrial glands (respectively, 100% and 81.8%). Increased HLA-G expression levels were observed in high histological grade (grade 3), and in the non-endometrioid type 2 EC. Unexpectedly, patients with IDO Low expression had significantly impaired overall survival compared to patients with IDO High (log-rank p = 0.021). Conversely, HLA-E low expression was associated to an improved overall survival EC (log-rank p = 0.004). We concluded that, HLA-G and IDO are highly expressed in EC compared to adjacent normal endometrial tissues, that might be interesting for the EC outcome.
Copyright © 2020 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; HLA-E; HLA-G; IDO; Immunohistochemistry

Mesh:

Substances:

Year:  2020        PMID: 32273131     DOI: 10.1016/j.humimm.2020.03.008

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  4 in total

Review 1.  Narrative review of the relationship between the maternal-fetal interface immune tolerance and the onset of preeclampsia.

Authors:  Fangyuan Luo; Jun Yue; Lingling Li; Jie Mei; Xinghui Liu; Yu Huang
Journal:  Ann Transl Med       Date:  2022-06

Review 2.  HLA-G and single nucleotide polymorphism (SNP) associations with cancer in African populations: Implications in personal medicine.

Authors:  Ismael Chatita Adolf; Amany Almars; Nazima Dharsee; Teddy Mselle; Gokce Akan; Irene Jeremiah Nguma; Abdolrahman S Nateri; Fatmahan Atalar
Journal:  Genes Dis       Date:  2021-06-30

Review 3.  HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies.

Authors:  Fabio Morandi; Irma Airoldi
Journal:  Int J Mol Sci       Date:  2022-03-08       Impact factor: 5.923

Review 4.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.